Azitra Q1 net loss $3.9M; adds MD Anderson for ATR-04 trial

Azitra, Inc.

• Net loss $3.9M ($1.6M R&D, $2.4M G&A); cash $10.1M at March 31, 2026.
• Added MD Anderson Cancer Center as clinical site for Phase 1/2 trial of ATR-04 targeting EGFRi-associated rash.
• Launched cosmeceutical initiative using filaggrin protein/peptide technologies for fine lines and wrinkles.
• Secured new U.S. patent for ATR-12 (Netherton syndrome); Phase 1b topline data expected H2 2026.
• Private placement financing of up to ~$10.5M (up to ~$20.9M if warrants exercised).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.